RBR-5pygzhj
Recruiting
Phase 2
A phase II single-arm clinical trial to evaluate the feasibility and efficacy of Neoadjuvant Anastrozole in luminal, low proliferative index Breast Cancer patients at TNM stages II and III
Hospital de Câncer de Barretos0 sitesJuly 18, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Malignant neoplasm of breast
- Sponsor
- Hospital de Câncer de Barretos
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or older; histologically confirmed unilateral primary invasive carcinoma of the breast;
- •estrogen receptor positive (Allread \=6\); progesterone receptor positive (any percentage value); HER\-2 negative; histological grade according to Scarf\-Bloom\-Richardson 1 or 2; Ki\-67 antigen \<50% on immunohistochemistry; TNM staging by 8th Edition cT2\-4c cNqq M0; tumor clinically palpable and larger than 2cm on palpation and/or imaging examination; functional capacity assessed by Eastern Cooperative Oncology Group Performance Status (ECOG\-PS) of 0 \- 2; adequate hematologic, renal, and hepatic function; absence of any psychological, familial, sociological, or geographic condition that would potentially hinder adherence to the study protocol and follow\-up schedule; patient agreeent to provide the required research biopsies from baseline, week 4 (re\-biopsy) and surgery for biomarker and biorepository research.
Exclusion Criteria
- •Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion; excisional biopsy of current breast cancer; hormone replacement therapy of any kind, megestrol acetate or raloxifene within one week prior to inclusion; axillary staging surgical procedure prior to study entry; clinical or radiographic evidence of metastatic disease; skin implants in the breast that prevent the required research biopsies or may interfere with palpation of the breast lesion; treatment for cancer, including surgery, radiation therapy, chemotherapy, biotherapy, hormone therapy, or any investigational product prior to study entry; history of previous invasive breast cancer; patient with any other concomitant serious and/or uncontrolled medical condition that may, in the opinion of the Investigator, cause unacceptable safety risks, contraindicate the patient's participation in the clinical trial or compromise adherence to the protocol (e.g. chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver disease, active, untreated or uncontrolled fungal, bacterial or viral infections, active infection requiring systemic antibacterial therapy, etc.) or limit life expectancy to \= 5 years.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
A research study to find The Effectiveness Of Varunmoola Kwatha Orally And Nirgundi Taila nasal drops In Kaphavrutta Vata disease With Special Reference To HypothyroidismCTRI/2020/03/024377DR Ashish Dattatray Kamble
Active, not recruiting
Phase 1
Study of the efficacy and safety of the Bintrafusp alfa (M7824) in previously treated cancer called malignant pleural mesothelioma.EUCTR2020-004902-67-ESFundación GECP47
Recruiting
Phase 2
A phase II trial to administrate Pembrolizumab for ovarian squamous cell carcinomaovarian squamous cell carcinomaJPRN-jRCT2031220701Yoshihara Kosuke21
Active, not recruiting
Phase 1
Clinical study to evaluate BO-112 plus pembrolizumab in patients with advanced melanomaAdvanced melanoma after progression to immunotherapyMedDRA version: 20.0Level: LLTClassification code 10027155Term: Melanoma skinSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-003921-51-FRHighlight Therapeutics40
Active, not recruiting
Phase 1
Clinical trial to evaluate the safety and immune activation of DCVAC/PCa and ONCOS-102 in men with metastatic prostate cancer.advanced metastatic castration-resistant prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-004314-15-CZSOTIO a.s.15